Alkan, Cigdem http://orcid.org/0000-0002-1302-9270
Jurado-Cobena, Eduardo http://orcid.org/0000-0002-8832-4645
Ikegami, Tetsuro http://orcid.org/0000-0001-8318-2783
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI150917, T32 AI007526-22)
The Sealy Institute of Vaccine Sciences (SIVS) at UTMB
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 27 April 2023
Accepted: 18 October 2023
First Online: 4 November 2023
Competing interests
: T.I. holds a patent for RVax-1 vaccine, which was submitted through UTMB (US11643640B2). Authors C.A. and E.J.C. declare no competing interests.